AEterna Zentaris Inc. (AEZS)
| Market Cap | 42.65M |
| Revenue (ttm) | 3.65M |
| Net Income (ttm) | -5.12M |
| Shares Out | 125.45M |
| EPS (ttm) | -0.07 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,426,635 |
| Open | 0.355 |
| Previous Close | 0.360 |
| Day's Range | 0.334 - 0.360 |
| 52-Week Range | 0.335 - 3.620 |
| Beta | 2.00 |
| Analysts | Buy |
| Price Target | 2.00 (+488.2%) |
| Earnings Date | Nov 4, 2021 |
About AEZS
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, a peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen name. Aeterna Zentaris Inc. has a license agreement with Julius-Maxi...
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for AEZS stock is "Buy" and the 12-month stock price forecast is 2.00.
News
Aeterna Zentaris to Present at the H.C. Wainwright BioConnect Conference
CHARLESTON, S.C., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...
Aeterna Zentaris Appoints Giuliano La Fratta as Chief Financial Officer
– Well-established finance professional with over 20 years of experience gained in pharmaceutical, biopharma and professional services sectors
3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Today
A few hot penny stocks are seeing major movement on Friday as shares ride higher and we've got all the details traders need. The post 3 Hot Penny Stocks: Why ZOM, AEZS and PROG Are Seeing Big Gains Toda...
Aeterna Zentaris to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLESTON, S.C., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified ...
Aeterna Zentaris Receives Nasdaq Notification Regarding Minimum Bid Price Compliance; No Immediate Impact on Listing
CHARLESTON, S.C., July 29, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...
Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs
– Dr. Levy is a well-established n euroimmunologist with extensive experience and expertise in the area of neuroimmunology, autoimmune and CNS disorders
Aeterna Zentaris Announces Final Settlement of Previously Disclosed Class-Action Lawsuit
CHARLESTON, S.C., June 03, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a ...
Aeterna Zentaris Announces the Start of Preclinical Development of Macimorelin at The University of Queensland as a P...
- Aeterna Zentaris granted exclusive option to negotiate a license of any resulting intellectual property and know-how developed by the University related to the therapeutic use of m acimorelin for the ...
Aeterna Zentaris Starts Research Study On How Well Macimorelin Works For Growth Hormone Deficiency Diagnosis
Aeterna Zentaris Inc (NASDAQ: AEZS) has commenced its pivotal Phase 3 DETECT trial evaluating macimorelin as a diagnosis of childhood-onset growth hormone deficiency (CGHD). The investigational new drug...
Aeterna Zentaris Commences Pivotal Phase 3 DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
– Safety and efficacy study for macimorelin initiated as agreed with U . S . FDA and the European Medicines Agency ("EMA") in the Company's Pediatric Investigation Plan ("PIP")
Aeterna Zentaris to Present at the Q2 Virtual Investor Summit
– Live video webcast with CEO, Dr. Klaus Paulini, on Monday, May 17, 2021 at 8:45 AM ET
Aeterna Zentaris Announces the Selection of a Development Candidate in the DC-PTH Program for the Potential Treatment...
In collaboration, Aeterna and The University of Sheffield, UK have selected the development candidate AEZS-150, a parathyroid hormone (PTH) fusion polypeptide to start the formal preclinical development...
Aeterna Zentaris Announces Results of 2021 Annual Meeting of Shareholders
CHARLESTON, S.C., May 05, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a d...
Aeterna Zentaris Reports First Quarter 2021 Financial Results and Provides Pipeline Program Updates
– Q1 2021 marked by solid operational execution with expansion and diversification of pipeline , intellectual property and portfolio of assets
Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientif...
– Over 20 years of industry experience in translating research into clinical development in a wide range of therapeutic areas of endocrinology and oncology
Aeterna Zentaris Announces Virtual 2021 Annual Meeting of Shareholders
CHARLESTON, S.C., April 28, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...
3 Penny Stocks to Watch During the Last Week of April
As April comes to an end, are these 3 penny stocks worth watching? The post 3 Penny Stocks to Watch During the Last Week of April appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...
Aeterna Zentaris Reports Fourth Quarter and Full Year 2020 Financial Results
– Company executing on growth strategy to build-out pipeline of development assets
Aeterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Requirement
CHARLESTON, S.C., March 22, 2021 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing t...
AEZS Stock: Why Aeterna Zentaris Shares Are Shooting Higher Today
Investors in AEZS stock have continued to pile into this trade today, with the stock up more than 40% on news around its Covid-19 vaccine. The post AEZS Stock: Why Aeterna Zentaris Shares Are Shooting H...
Aeterna Zentaris Shares Are Trading Higher On Announcing Licensing Pact For Development Of Prophylactic COVID-19 Vacc...
Aeterna Zentaris Inc (NASDAQ: AEZS) has exercised its option announced on February 2, and entered into an exclusive worldwide sub-licensable patent and know-how license agreement for a potential COVID-1...
Aeterna Zentaris Announces Exclusive License Agreement and Research Contract with Julius-Maximilians-University Wuerz...
- Company secures next step to continue to build-out pipeline of assets
If You Like Long Shots, Aeterna Zentaris Stock Is Worth a Gamble
AEZS stock isn't something to bet your entire portfolio on, but since the company's a Covid-19 vaccine contender, it might be worth owning. The post If You Like Long Shots, Aeterna Zentaris Stock Is Wor...
Aeterna Zentaris Continues to Demonstrate Pipeline Expansion – Announces the Initiation of Its Preclinical Program fo...
– Company obtains an exclusive license from The University of Sheffield, UK to intellectual property relating to parathyroid hormone (PTH) fusion polypeptides covering the field of human use which will ...